An analysis of for-profit kidney dialysis centers published in the medical journal JAMA Internal Medicine found that they used more of an expensive and dangerous class of drugs known as erythropoiesis-stimulation agents (ESAs) than non-profit facilities.
This isn’t the first time that commercial dialysis centers have been accused of engaging in unsafe practices.
The U.S. Food and Drug Administration is investigating allegations that Fresenius, a German company that is the largest operator ...
continue reading...
A number of the world’s top diabetes experts agree with Dr. Peter C. Butler, an internationally renowned physician who raised alarms about the diabetes drugs Januvia and Byetta.
Ranbaxy, a subsidiary of Japanese pharmaceutical company Daiichi Sankyo, has pleaded guilty to drug safety violations. According to a story in the New York Times, the company will pay $500 million in fines over allegations that it sold subpar drugs.
Reuters reports on a recently approved intrauterine device from Bayer, which is the first new device of its type that the FDA has approved in 12 years.
The prestigious medical journal BMJ has published a damning investigative article on a crop of new diabetes drugs called “incretin therapies,” which include Byetta and Januvia.
According to British newspaper the Mansfield and Ashfield Chad, a 26-year-old man left disabled from birth because of a traumatic brain injury has successfully sued for damages.
